Sickle cell disease: time for a closer look at treatment options?

British Journal of Haematology

Volumn 162, Issue 4, 2013, Pages 455-464

  Sheth, Sujit ^a   Licursi, Maureen ^b,c   Bhatia, Monica ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Hydroxycarbamide; Morbidity; Sickle cell disease; Stem cell transplantation

Indexed keywords

HAEMOPHILUS INFLUENZAE VACCINE; HYDROXYUREA; IRON CHELATING AGENT; PENICILLIN DERIVATIVE; PLACEBO; PNEUMOCOCCUS VACCINE;

ALLOIMMUNIZATION; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; GRAFT VERSUS HOST REACTION; HAEMOPHILUS INFECTION; HEALTH CARE COST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; IRON OVERLOAD; LIFE EXPECTANCY; MEDICAL DECISION MAKING; MORTALITY; NEUTROPENIA; ORGAN INJURY; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; STREPTOCOCCUS PNEUMONIA; SURVIVAL TIME; VASCULAR DISEASE;

HYDROXYCARBAMIDE; MORBIDITY; SICKLE CELL DISEASE; STEM CELL TRANSPLANTATION;

AFRICA; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; BRAIN DAMAGE, CHRONIC; CARDIOVASCULAR DISEASES; CHELATION THERAPY; CHRONIC PAIN; COMBINED MODALITY THERAPY; COST OF ILLNESS; DEVELOPING COUNTRIES; DISEASE MANAGEMENT; DISEASE PROGRESSION; FORECASTING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; IRON OVERLOAD; LIFE EXPECTANCY; PAIN MANAGEMENT; PATIENT PARTICIPATION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; STROKE; UNITED STATES;

EID: 84880698186     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12413     Document Type: Review

References (53)

1. Abboud, M.R., Yim, E., Musallam, K.M., Adams, R.J. & STOP II Study Investigators. (2011) Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood, 118, 894-898.
2. Adamkiewicz, T.V., Szabolcs, P., Haight, A., Baker, K.S., Staba, S., Kedar, A., Chiang, K.Y., Krishnamurti, L., Boyer, M.W., Kurtzberg, J., Wagner, J.E., Wingard, J.R. & Yeager, A.M. (2007) Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatric Transplantation, 11, 641-644.
3. Adams, R.J., McKie, V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F.T., Bonds, D.R. & Brambilla, D. (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine, 339, 5-11.
4. Ballas, S.K., Bauserman, R.L., McCarthy, W.F., Waclawiw, M.A. & Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (2010) The impact of hydroxyurea on career and employment of patients with sickle cell anemia. Journal of the National Medical Association, 102, 993-999.
5. Bernaudin, F. (1999) Results and current indications of bone marrow allograft in sickle cell disease. Pathologie-Biologie, 47, 59-64. French.
6. Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.P., Yakouben, K., Thuret, I., Bordigoni, P., Fischer, A., Lutz, P., Stephan, J.L., Dhedin, N., Plouvier, E., Margueritte, G., Bories, D., Verlhac, S., Esperou, H., Coic, L., Vernant, J.P., Gluckman, E. & SFGM-TC. (2007) Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood, 110, 2749-2756.
7. Bishop, S., Matheus, M.G., Abboud, M.R., Cane, I.D., Adams, R.J., Jackson, S.M. & Kalpatthi, R. (2011) Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia. Blood Cells, Molecules & Diseases, 47, 125-128.
8. Bolaños-Meade, J., Fuchs, E.J., Luznik, L., Lanzkron, S.M., Gamper, C.J., Jones, R.J. & Brodsky, R.A. (2012) HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood, 120, 4285-4291.
9. Brawley, O.W., Cornelius, L.J., Edwards, L.R., Gamble, V.N., Green, B.L., Inturrisi, C., James, A.H., Laraque, D., Mendez, M., Montoya, C.J., Pollock, B.H., Robinson, L., Scholnik, A.P. & Schori, M. (2008) National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Annals of Internal Medicine, 148, 932-938.
10. Charache, S., Terrin, M.L., Moore, R.D., Dover, G.J., Barton, F.B., Eckert, S.V., McMahon, R.P. & Bonds, D.R. (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New England Journal of Medicine, 332, 1317-1322.
11. Dampier, C., LeBeau, P., Rhee, S., Lieff, S., Kesler, K., Ballas, S., Rogers, Z., Wang, W. & Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site Investigators. (2011) Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. American Journal of Hematology, 86, 203-205.
12. DeBaun, M.R. & Telfair, J. (2012) Transition and sickle cell disease. Pediatrics, 130, 926-935.
13. DeBaun, M.R., Armstrong, F.D., McKinstry, R.C., Ware, R.E., Vichinsky, E. & Kirkham, F.J. (2012) Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood, 119, 4587-4596.
14. Ferster, A., Vermylen, C., Cornu, G., Buyse, M., Corazza, F., Devalck, C., Fondu, P., Toppet, M. & Sariban, E. (1996) Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood, 88, 1960-1964.
15. Gladwin, M.T., Sachdev, V., Jison, M.L., Shizukuda, Y., Plehn, J.F., Minter, K., Brown, B., Coles, W.A., Nichols, J.S., Ernst, I., Hunter, L.A., Blackwelder, W.C., Schechter, A.N., Rodgers, G.P., Castro, O. & Ognibene, F.P. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. New England Journal of Medicine, 350, 886-895.
16. Hassell, K.L. (2010) Population estimates of sickle cell disease in the U.S. American Journal of Preventive Medicine, 38, S512-S521.
17. Herrick, J.B. (1910) Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Archives of Internal Medicine, 6, 517-521.
18. Hijmans, C.T., Fijnvandraat, K., Grootenhuis, M.A., van Geloven, N., Heijboer, H., Peters, M. & Oosterlaan, J. (2011) Neurocognitive deficits in children with sickle cell disease: a comprehensive profile. Pediatric Blood and Cancer, 56, 783-788.
19. Hsieh, M.M., Kang, E.M., Fitzhugh, C.D., Link, M.B., Bolan, C.D., Kurlander, R., Childs, R.W., Rodgers, G.P., Powell, J.D. & Tisdale, J.F. (2009) Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. New England Journal of Medicine, 361, 2309-2317.
20. Hsieh, M.M., Fitzhugh, C.D. & Tisdale, J.F. (2011) Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood, 118, 1197-1207.
21. Iannone, R., Casella, J.F., Fuchs, E.J., Chen, A.R., Jones, R.J., Woolfrey, A., Amylon, M., Sullivan, K.M., Storb, R.F. & Walters, M.C. (2003) Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biology of Blood and Marrow Transplantation, 9, 519-528.
22. Johnson, F.L., Look, A.T., Gockerman, J., Ruggiero, M.R., Dalla-Pozza, L. & Billings, F.T. 3rd (1984) Bone-marrow transplantation in a patient with sickle-cell anemia. New England Journal of Medicine, 311, 780-783.
23. Kamani, N.R., Walters, M.C., Carter, S., Aquino, V., Brochstein, J.A., Chaudhury, S., Eapen, M., Freed, B.M., Grimley, M., Levine, J.E., Logan, B., Moore, T., Panepinto, J., Parikh, S., Pulsipher, M.A., Sande, J., Schultz, K.R., Spellman, S. & Shenoy, S. (2012) Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biology of Blood and Marrow Transplantation, 18, 1265-1272.
24. Kinney, T.R., Helms, R.W., O'Branski, E.E., Ohene-Frempong, K., Wang, W., Daeschner, C., Vichinsky, E., Redding-Lallinger, R., Gee, B., Platt, O.S. & Ware, R.E. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood, 94, 1550-1554.
25. Krishnamurti, L., Kharbanda, S., Biernacki, M.A., Zhang, W., Baker, K.S., Wagner, J.E. & Wu, C.J. (2008) Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biology of Blood and Marrow Transplantation, 14, 1270-1278.
26. Locatelli, F., Rocha, V., Reed, W., Bernaudin, F., Ertem, M., Grafakos, S., Brichard, B., Li, X., Nagler, A., Giorgiani, G., Haut, P.R., Brochstein, J.A., Nugent, D.J., Blatt, J., Woodard, P., Kurtzberg, J., Rubin, C.M., Miniero, R., Lutz, P., Raja, T., Roberts, I., Will, A.M., Yaniv, I., Vermylen, C., Tannoia, N., Garnier, F., Ionescu, I., Walters, M.C., Lubin, B.H., Gluckman, E. & Eurocord Transplant Group. (2003) Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood, 101, 2137-2143.
27. McMahon, L., Tamary, H., Askin, M., Adams-Graves, P., Eberhardt, R.T., Sutton, M., Wright, E.C., Castaneda, S.A., Faller, D.V. & Perrine, S.P. (2010) A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers. British Journal of Haematology, 151, 516-524.
28. Mehari, A., Gladwin, M.T., Tian, X., Machado, R.F. & Kato, G.J. (2012) Mortality in adults with sickle cell disease and pulmonary hypertension. Journal of the American Medical Association, 28, 1254-1256.
29. Modell, B. & Darlison, M. (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization, 86, 480-487.
30. Panepinto, J.A. & Bonner, M. (2012) Health-related quality of life in sickle cell disease: past, present, and future. Pediatric Blood and Cancer, 59, 377-385.
31. Panepinto, J.A., Walters, M.C., Carreras, J., Marsh, J., Bredeson, C.N., Gale, R.P., Hale, G.A., Horan, J., Hows, J.M., Klein, J.P., Pasquini, R., Roberts, I., Sullivan, K., Eapen, M., Ferster, A., Non-Malignant Marrow Disorders Working Committee & Center for International Blood and Marrow Transplant Research. (2007) Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. British Journal of Haematology, 137, 479-485.
32. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639-1644.
33. Quinn, C.T., Rogers, Z.R., McCavit, T.L. & Buchanan, G.R. (2010) Improved survival of children and adolescents with sickle cell disease. Blood, 115, 3447-3452.
34. Radhakrishnan, K., Bhatia, M., Geyer, M.B., Del Toro, G., Jin, Z., Baker, C., Harrison, L., Morris, E., Baxter-Lowe, L.A. & Cairo, M.S. (2013) Busulfan, Fludarabine and Alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biology of Blood and Marrow Transplantation, 19, 676-677.
35. Rigano, P., Rodgers, G.P., Renda, D., Renda, M.C., Aquino, A. & Maggio, A. (2001) Clinical and hematological responses to hydroxyurea in Sicilian patients with Hb S/beta-thalassemia. Hemoglobin, 25, 9-17.
36. Roth, M., Krystal, J., Manwani, D., Driscoll, C. & Ricafort, R. (2012) Stem cell transplant for children with sickle cell anemia: parent and patient interest. Biology of Blood and Marrow Transplantation, 18, 1709-1715.
37. Shenoy, S. (2011) Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology 2011, American Society of Hematology Educational Program, 273-279.
38. Shenoy, S., Grossman, W.J., DiPersio, J., Yu, L.C., Wilson, D., Barnes, Y.J., Mohanakumar, T., Rao, A. & Hayashi, R.J. (2005) A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplantation, 35, 345-352.
39. Steen, R.G., Fineberg-Buchner, C., Hankins, G., Weiss, L., Prifitera, A. & Mulhern, R.K. (2005) Cognitive deficits in children with sickle cell disease. Journal of Child Neurology, 20, 102-107.
40. Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. Journal of the American Medical Association, 289, 1645-1651.
41. Steinberg, M.H., McCarthy, W.F., Castro, O., Ballas, S.K., Armstrong, F.D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., Waclawiw, M.A. & Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. American Journal of Hematology, 85, 403-408.
42. Steiner, C.A. & Miller, J.L. (2006) Sickle Cell Disease Patients in U.S. Hospitals, 2004: Statistical Brief #21. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006.
43. Thompson, A.A. (2011) Primary prophylaxis in sickle cell disease: is it feasible? Is it effective? Hematology 2011, American Society of Hematology Educational Program, 434-439.
44. Thornburg, C.D., Files, B.A., Luo, Z., Miller, S.T., Kalpatthi, R., Iyer, R., Seaman, P., Lebensburger, J., Alvarez, O., Thompson, B., Ware, R.E., Wang, W.C. & BABY HUG Investigators. (2012) Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood, 120, 4304-4310.
45. Vermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., Beguin, Y., Dresse, M.F. & Sariban, E. (1998) Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplantation, 22, 1-6.
46. Vichinsky, E.P., Neumayr, L.D., Gold, J.I., Weiner, M.W., Rule, R.R., Truran, D., Kasten, J., Eggleston, B., Kesler, K., McMahon, L., Orringer, E.P., Harrington, T., Kalinyak, K., De Castro, L.M., Kutlar, A., Rutherford, C.J., Johnson, C., Bessman, J.D., Jordan, L.B., Armstrong, F.D. & Neuropsychological Dysfunction and Neuroimaging Adult Sickle Cell Anemia Study Group. (2010) Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. Journal of the American Medical Association, 303, 1823-1831.
47. Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D. & Terpos, E. (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 115, 2354-2363.
48. Walters, M.C., Storb, R., Patience, M., Leisenring, W., Taylor, T., Sanders, J.E., Buchanan, G.E., Rogers, Z.R., Dinndorf, P., Davies, S.C., Roberts, I.A., Dickerhoff, R., Yeager, A.M., Hsu, L., Kurtzberg, J., Ohene-Frempong, K., Bunin, N., Bernaudin, F., Wong, W.Y., Scott, J.P., Margolis, D., Vichinsky, E., Wall, D.A., Wayne, A.S., Pegelow, C., Redding-Lallinger, R., Wiley, J., Klemperer, M., Mentzer, W.C., Smith, F.O. & Sullivan, K.M. (2000) Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood, 95, 1918-1924.
49. Walters, M.C., Patience, M., Leisenring, W., Rogers, Z.R., Aquino, V.M., Buchanan, G.R., Roberts, I.A., Yeager, A.M., Hsu, L., Adamkiewicz, T., Kurtzberg, J., Vichinsky, E., Storer, B., Storb, R., Sullivan, K.M. & Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. (2001) Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biology of Blood and Marrow Transplantation, 7, 665-673.
50. Wang, W., Enos, L., Gallagher, D., Thompson, R., Guarini, L., Vichinsky, E., Wright, E., Zimmerman, R., Armstrong, F.D. & Cooperative Study of Sickle Cell Disease. (2001) Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. Journal of Pediatrics, 139, 391-397.
51. Wang, W.C., Ware, R.E., Miller, S.T., Iyer, R.V., Casella, J.F., Minniti, C.P., Rana, S., Thornburg, C.D., Rogers, Z.R., Kalpatthi, R.V., Barredo, J.C., Brown, R.C., Sarnaik, S.A., Howard, T.H., Wynn, L.W., Kutlar, A., Armstrong, F.D., Files, B.A., Goldsmith, J.C., Waclawiw, M.A., Huang, X., Thompson, B.W. & BABY HUG investigators. (2011) Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, 377, 1663-1672.
52. Wayne, A.S., Schoenike, S.E. & Pegelow, C.H. (2000) Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood, 96, 2369-2372.
53. Yanni, E., Grosse, S.D., Yang, Q. & Olney, R.S. (2009) Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. Journal of Pediatrics, 154, 541-545.